Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00327223 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy
A Phase 1 study, sponsored by AmpliMed Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00327223: Completed Phase 1 study, sponsored by AmpliMed Corporation.
NCT00327223 is a Phase 1 study that has completed, run by AmpliMed Corporation. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00327223, a Phase 1 study, has completed, sponsored by AmpliMed Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three weeks. The objective of the study is to determine the maximally tolerated dose, the pharmacokinetics, and the toxicity of the drug on the designated schedule.
Interventions
- DRUG imexon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
What the finished NCT00327223 record still lists
NCT00327223 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which imexon is the first listed.
NCT00327223 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00327223 about?
NCT00327223 is a clinical study titled "Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy". AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three weeks. The objective of the study is to determine the maximally tolerated dose, the pharmacokinetics, and the toxicity of t...
What is the current status of trial NCT00327223?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2005-11. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00327223?
The interventions under investigation include: imexon (DRUG).
Who is sponsoring clinical trial NCT00327223?
This trial is sponsored by AmpliMed Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00327223's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia